U.S. Actinium Company's ATNM-400 Achieves 94.29% Tumor Inhibition Rate in Prostate Cancer Model
The radioconjugate ATNM-400 demonstrated superior antitumor activity compared to existing PSMA-targe...
Ultragenyx to Participate in Goldman Sachs Global Healthcare Conference
On June 3, U.S. biopharmaceutical company Ultragenyx Pharmaceutical announced that its President and...
MEDIPOST's Knee Osteoarthritis Product Receives FDA Approval to Initiate Pivotal Phase 3 Study
MEDIPOST, a South Korean company, recently announced that its knee osteoarthritis treatment product ...
Brazil's Vesper Launches $15 Million Funding Round to Co-Develop AI Biotechnology
Brazilian biotech startup studio Vesper Biotechnologies, after receiving investment from the Lafer f...
Zhuhai Selected as National Tech Transformation Pilot City, to Receive 300 Million Yuan Support
The Ministry of Industry and Information Technology organized expert evaluations, and Zhuhai has bee...
US Capricor DMD Therapy Under FDA Review, August 2026
Capricor Therapeutics Inc. (CAPR:NASDAQ) reported its first-quarter 2026 financial results and discl...
US-based Made Scientific to Manufacture NOVAKnee Implants
US cell therapy contract development and manufacturing organization (CDMO) Made Scientific has been ...
Spanish Report: Vyjuvek Achieves 67.4% Healing Rate for Butterfly Skin Disease
The gene therapy Vyjuvek (beremagene geperpavec) has recently received a Therapeutic Positioning Rep...
U.S. Study: GLP-1 Drug Users See 35% Lower Breast Cancer Diagnosis Rate
An observational study led by Elizabeth McDonald, a professor of radiology at the Perelman School of...
ASCO 2026: InnoCare Pharma's Mesutoclax Achieves 100% Overall Response Rate in Treatment-Naïve MDS
InnoCare Pharma (HKEx: 09969; SSE: 688428) presented updated clinical data on its novel BCL2 inhibit...
Johnson & Johnson Releases Nipocalimab Data for Sjögren's Syndrome, Response Rate Reaches 62.5% in High Autoantibody Subgroup
On June 3, Johnson & Johnson announced new exploratory biomarker analyses from the Phase 2 DAHLI...
China's Chen Lei Establishes World's First Female Epilepsy Diagnosis and Treatment Ontology Database, Infertility Rate Drops to 12.8%
Chen Lei, Vice Dean of West China Clinical Medical College of Sichuan University, Chief Physician an...
Johnson & Johnson's Nipocalimab Meets Primary Endpoint in Phase 2 Study for Systemic Lupus Erythematosus
Johnson & Johnson presented detailed results from the Phase 2 JASMINE study of the FcRn blocker nipo...
Germany's FundaMental Pharma Appoints Chief Medical Officer
FundaMental Pharma GmbH announced the appointment of Dr. Hans Eriksson as Chief Medical Officer, whe...
Asahi Kasei Life Science Licenses ADC Technology from Noguchi Institute
Asahi Kasei Life Science announced a technology licensing and collaboration agreement with the Noguc...
US-based RayzeBio Plans $150 Million Investment in Radiopharmaceutical Facility
On June 1, RayzeBio, a subsidiary of Bristol Myers Squibb, announced plans to invest approximately $...
Zhejiang, China Launches 225Ac-PSMA Clinical Study for Prostate Cancer and Completes First Patient Dosing
The Department of Nuclear Medicine at Zhejiang Cancer Hospital recently initiated an international m...
U.S. Bio-IT World Focuses on AI Drug Discovery, Collaborative Intelligence Becomes New Variable in Life Sciences R&D
In the keynote speeches on the second day of the 2026 Bio-IT World conference, multiple experts disc...
UK's Quotient Sciences Initiates Phase I Clinical Trial of AI-Designed Formulation
Quotient Sciences has initiated a clinical study to evaluate a novel drug product developed using ar...
CEPI Invests Over $60 Million to Accelerate Bundibugyo Ebola Vaccine Amid DRC Outbreak
The Coalition for Epidemic Preparedness Innovations (CEPI) announced emergency funding for three inv...
Novo Nordisk's Wegovy Oral Drug Receives Positive European Review, Plans to Launch in Spain
The European Medicines Agency has issued a positive review for the oral therapy Wegovy (semaglutide)...
China's self-developed first-in-class drugs entering clinical trials have increased 12-fold in a decade
The number of China's self-developed First-in-Class (FIC) drug candidates entering clinical trials g...
Newcastle University Develops ReJI Bioprinted 3D Tissue Models for Drug Screening
Dr. Priscila Melo, a Lecturer in Bioengineering at Newcastle University and co-founder of JetBio, is...
CorrectSequence's CS-206 Therapy Shows 15 Months Without Vaso-Occlusive Crisis
CorrectSequence Therapeutics Co., Ltd. has announced 15-month follow-up data for CS-206, a high-prec...
Australia's first $96 million RNA manufacturing facility opens in New South Wales
Australia's first dedicated RNA research and manufacturing facility, designed by HDR, has officially...
Japan's iPS Cell Regenerative Medicine Products Approved, Heart Failure and Parkinson's Treatment Entering New Clinical Application Stage
Japan's Ministry of Health, Labour and Welfare recently approved two regenerative medicine products ...
On May 29, China's Shenzhou returned space science samples, with a total weight of 41 kg including artificial embryos
The tenth batch of space science experiment samples from the China Space Station returned to Earth a...